Article Abstract

TAZ teases T cells with PD-L1

Authors: Ryan Kanai, John M. Lamar

Abstract

Metastatic cancer continues to be a devastating disease with few effective treatment options. One promising approach that has emerged recently is immunotherapy, and the immune checkpoint protein programmed death-ligand 1 (PD-L1) has garnered particular interest given its role in immune system evasion by cancer cells (1,2).

Article Options

Download Citation